Stories

Biotech CDMOs and the Shift Toward Outsourced Drug Development

Biotech companies are increasingly outsourcing drug development and manufacturing to CDMOs rather than building in-house facilities, driven by molecule complexity, capital efficiency, and speed-to-clinic pressures in the pharmaceutical industry.

From Route Scouting to Kilo Labs: The R&D Journey in Contract Drug Manufacturing

Contract drug manufacturing involves outsourcing R&D and production to specialized partners (CDMOs) who guide molecules through interconnected stages, from route scouting and process development to kilo lab production.

What Is a CDMO? The Complete Guide to Contract Development & Manufacturing (2026)

A comprehensive guide explaining what CDMOs are, how they differ from CMOs and CROs, and why pharmaceutical companies increasingly outsource drug development and manufacturing to specialized partners.

Enterprise Risk Management (ERM) for CDMOs: A Structured, Forward-Looking Framework

Neuland Labs outlines how Contract Development and Manufacturing Organizations can implement structured Enterprise Risk Management frameworks to identify, assess, and mitigate operational, regulatory, and strategic risks across their manufacturing and supply chain operations.

CDMO API Manufacturing for Complex Molecules

A guide to CDMO API manufacturing for complex molecules, covering process development, scale-up, GMP compliance, and how to select the right contract partner.

From Anxiety to Assurance: Transforming CDMO Audits Through a Quality First Culture

CDMO Failures Still Happen. Is Quality Maturity the Solution?

How CDMO Partnerships Improve R&D ROI for Biopharma Companies

Speed and Flexibility: The Defining Metrics for Finding a CDMO You Can Trust